LEADER 01630nam  2200397Ia 450 
001 9910698736003321
005 20090420160359.0
035   $a(CKB)5470000002396497
035   $a(OCoLC)318815382
035   $a(EXLCZ)995470000002396497
100   $a20090420d2008      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aE2f development safety update report$b[electronic resource]
210  1$a[Silver Spring, MD] :$c[Center for Drug Evaluation and Research] ;$a[Rockville, MD]:$c[U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research],$d[2008]
215   $a33 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on Apr. 20, 2009).
300   $a"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use"--PDF p.1.
300   $a"ICH harmonised tripartite guideline"--PDF p. 1.
300   $a"Draft"-- PDF p. 1.
300   $a"Current step 2 version, 05 June 2008"--PDF p. 1.
517 3 $aDevelopment safety update report
606   $aDrug development$xEvaluation
615  0$aDrug development$xEvaluation.
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
712 12$aInternational Conference on Harmonisation.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698736003321
996   $aE2f development safety update report$93140620
997   $aUNINA